Careers
Together,
we can accomplish more.
If you’re patient focused, passionate about what you do, and have an entrepenuerial spirit, you might be interested in learning more about working with us.
Explore Renibus’ career opportunities:

Join Our Team
Document Specialist
Renibus is a clinical-stage biotech company focused on the prevention and treatment of cardo-renal diseases. Our team is conducting a Phase 3 trial with RBT-1, a novel drug which is being studied in patients undergoing cardiac surgery. Our phase 2 clinical data suggests that the treatment can improve outcomes. The U.S. FDA has granted RBT-1 a fast track and Breakthrough Therapy designation, which speaks to the promise of the drug. We are seeking a Document Specialist to be a part of our dynamic, passionate, and driven team that values collaboration, innovation, and diversity. This individual, through collaboration with various team members, is accountable for the creation, maintenance and archival of the Trial Master Files/ eTrial Master Files to ensure audit readiness. A minimum of 3 years’ experience in the use of an eTMF system and knowledge of the TMF Reference Model, supported by DIA is preferred.
Sr. Clinical Trial Manager
Renibus is a clinical-stage biotech company focused on the prevention and treatment of cardo-renal diseases. Our team is conducting a Phase 3 trial with RBT-1, a novel drug which is being studied in patients undergoing cardiac surgery. Our phase 2 clinical data suggests that the treatment can improve outcomes. The U.S. FDA has granted RBT-1 a fast track and Breakthrough Therapy designation, which speaks to the promise of the drug. We are seeking a Sr. Clinical Trial Manager to be a part of our dynamic, passionate, and driven team that values collaboration, innovation, and diversity. This individual will assist with our phase 3 trial, providing day-to-day, site facing, operations of the project, and ensuring deliverables are met in terms of quality, compliance, and timing. Comprehensive knowledge of clinical trial regulations, guidelines, and best practices, including ICH-GCP is required. A Bachelor’s degree in a health-related field and a minimum of 5 years as a project/clinical trial manager is preferred.


About Renibus Therapeutics
Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients’ lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus’ first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations.
Veverimer (Alezuris™) is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in a Phase 2 trial.
RBT-3 (iron sucrose), one component of RBT-1, is a novel, low molecular weight iron nanoparticle that has the potential to rapidly restore iron levels and improve blood product utilization in cardiac surgery and/or ER patients. RBT-3 has also demonstrated the potential to mitigate cisplatin induced nephrotoxicity in preclinical models. We are currently exploring opportunities to further the clinical development of RBT-3 in these potential indications.
RBT-9 (stannic protoporfin), another component of RBT-1, is a potent anti-inflammatory and antioxidant drug. It has completed Phase 1 (as part of the RBT-1 program) and has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. The data from this trial indicated that RBT-9 has the potential to significantly improve clinical outcomes. Additional work is underway to help inform the future clinical development strategy.
RBT-2 (tetrahydrocurcumin) is an oral antioxidant and antifibrotic drug that is in IND enabling studies targeting delaying CKD progression.
Submit Your Resume
"*" indicates required fields